ß-palmitate
The triglyceride molecule of breast milk fat
has a specific composition (the same in hu-
mans all over the world), with a saturated
palmitic fatty acid (C16:0) in the central,
(sn-2 or ß) position and mainly unsaturated
fatty acids (C18:1) in the outer (sn-1,3 or α)
positions in the triglyceride. A glyceride with
palmitic fatty acid in the ß position is called
ß-palmitate.
The benefits of this triglycerid is explained
more in detail on page 5-6.
Infant Nutrition
2
Akonino – tailor made blends – AAK takes responsibility
Breast milk – the reference level of 1-2 % of linolenic acid (18:3) and a composition very close to that of breast
The reference for infant formula is breast part of the linoleic (18:2). milk. In this blend the linolenic acid is sup-
milk. An important aim is therefore to mimic In most cases at least one more liquid oil plied by rapeseed oil. Akonino NR is a simi-
the fat composition of human breast milk. is needed to provide the desired levels of lar blend where the linolenic acid comes
To achieve this, a number of different oils linoleic and oleic acid. from soyabean oil instead.
needs to be blended. Akonino SC is a blend comprising MCT
Akonino range oils, which are used in special formulas
Specified fat composition Most Akonino products are tailor made in for preterm infants. MCT oils are based on
A tailor made blend for an infant formula cooperation with the customer, some ex- short chain fatty acids (C8, C10) and as
may comprise up to five components of amples of standard products are described such are appreciated as an efficient source
specified proportions, in order to come as below. of energy.
close as possible to the fat composition in Akonino NS is a typical example of a
breast milk. blend for a standard infant formula, with
Different oils contribute with different
fatty acids providing the total composition
to be in line with the specification. AAK can Fatty acid composition of some typical Akonino products
provide a wide range of oils to fulfill any re-
Fatty acid Breast
quirement on composition.
profile (%) milk Akonino NS Akonino NR Akonino SC InFat 194D
Saturated fat from palm and laurics C8 0.6 0.5 2.2 30 0.8
Palm oil provides palmitic acid, which is the
predominant saturated fatty acid. To reach C10 1 0.5 1.8 20 0.8
the level of 20-25 % found in breast milk,
40-50 % palm oil or palm olein is required. C12 6.2 6 14.7 4.5 11
To get even closer to breast milk, palm oil
should be replaced by InFat, the product C14 7.8 2.5 5.9 1.5 4
described in pages 5-6.
In addition, coconut or palmkernel oil is C16 25 23 22.5 4.2 19
needed to provide the shorter-chain fatty
C18:0 8.7 3 3.7 1.4 4
acids.
Infant Nutrition
3
Akonino – tailor made blends – AAK takes responsibility
Guaranteed specification
After agreeing on a specification for the
complete blend, AAK will take the responsi-
bility to ensure that the specification is met
for each delivery. This saves the extra work
for the producer, who has to optimize the
composition depending on variations in the
raw materials. When buying a tailor made
Akonino blend, this optimization is handled
by AAK.
Application of Akonino
There is a strong regulation, regarding in-
fant formulae. As this is the only processed
food satisfying the needs of a growing baby.
It varies between different countries hereby
illustrated by part of the EC regulation.
Starter Follow up
formula formula
Fat 24 % 20 % EC-directive
According to the EC directive 2006/141/EC fats for use in both starter and
Protein 11 % 11 %
follow up formulas have to comply with the following points:
Fat content of reconstituted product between 1.05 and 1.4 g/100 kJ
Carbohydrates 50 % 56 %
For allergenic reason the use of sesame and cottonseed oil is not allowed
The sum of Lauric acid (C12) and Myristic acid (C14): maximum 20 %
Akoninos are designed to fulfill the EC leg-
islation and can thereby be applied to the Content of α-linolenic acid: minimal 12 mg/100kJ
formula in the concentration of 24 % in a Linoleic acid: between 70-285 mg/100 kJ
starter formula and 20 % in a follow on for- Ratio between linoleic and α-linolenic: minimal 5 and maximal 15
mula. Trans fatty acids: maximum 3 % of total fat content
Erucic acid: maximum 1 % of total fat content
Infant Nutrition
4
InFat – closer to mother’s milk
Infant Nutrition
5
InFat in new clinical study, presented at ESPGHAN
Advanced Lipids presented a poster at the ESPGHAN Meeting in Sorrento May 2011
New clinical studies Society for Paediatric Gastroenterology, Hepa- the clinical study when it is officially pub-
In 2010, new clinical studies demonstrating togology and Nutrition) end of May 2011. lished.
the effect of InFat in term babies had been The clinical study is right now under pre- Advanced Lipids has already started
concluded by Enzymotec. review before it will be published in scien- more clinical studies based on InFat, so you
Preliminary results were presented at the tific journals. can expect more interesting new findings in
ESPGHAN annual meeting (The European You will hear more about the outcome of the coming years.
Advanced Lipids
Combining Enzymotec and AAK strengths Enzymotec
Delivering Lipids
Advanced Lipids is a joint venture be-
tween Enzymotec, a global biotech com- + Worldwide expert in lipids + Worldwide expert in lipids
pany that develops and manufactures lip- technology technology
id-based bio-functional and nutraceutical + Global leader in fats for infant + Proven capabilities in supplying
ingredients; and AAK, the world’s leading nutrition innovative lipidbased, biofunctio-
nal ingredients and final products
producer of vegetable fats and oils for the + Global supplier of tailor-made
oils for infant formula producers + High standard clinical trials
infant formula industry. Advanced Lipids
provides a unique service package to our + State of the art production + Global business development
facilities
customers, thru combining Enzymotec’s + Intellectual property
+ High level of product quality
clinical R&D and expertise in lipid tech- and food safety + Regulatory expertise
nologies with AAK’s international strength
in food safety, production and logistics.
Advanced Lipids continuously invests in InFat Production Facility factory designed for continuous operation,
InFat clinical research and owns several The InFat production plant is located in the equipped with the latest technology for the
patents and patents pending in the area of AAK facility in Karlshamn, Sweden. The enzymatic production of structured triglyc-
infant nutrition. plant is a state of the art fully automated erides of the type found in mother’s milk.